Market Access & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical need to patients faster were successful last month.
Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.
Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.
The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.